Iktos Roman Fleck
Iktos announces the appointment of Roman Fleck as Chairman of the Board  
May 02, 2024 02:45 ET | IKTOS
Paris (France), 2nd May 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of Roman Fleck as Chairman of the Board. Yann Gaston-Mathé steps...
Screenshot 2023-07-03 110159.png
Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji
February 14, 2024 03:00 ET | IKTOS
Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan....
Centogene_Logo.png
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
January 25, 2024 06:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
Iktos
PR : Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery
January 08, 2024 02:00 ET | ULYSSE COMMUNICATION
Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery Paris, France, 8 January, 2023 – Iktos, a company specialized in Artificial...
Centogene_Logo.png
CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer
March 17, 2022 06:30 ET | Centogene NV
In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical targets for the potential development of new...
The Antibody Society Logo
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
November 11, 2021 10:08 ET | LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...
LavaTx_RGB.jpg
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
November 02, 2021 07:00 ET | Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...